News

The phase II trial evaluated four intravenous doses of secretin versus a placebo in refractory schizophrenia. Initial results showed that secretin did not significantly improve symptoms as measured

Orphan drug designation entitles Viventia to various incentives, including seven years of exclusive marketing rights if Proxinium receives marketing approval by the FDA. Historically, many orphan drugs have

The Division of Drug Marketing, Advertising, and Communications (DDMAC) reviewed advertising information for Coreg (carvedilol) tablets and found it to be false or misleading, as it omits material

Pegamotecan is a PEGylated cytotoxic drug of the topoisomerase I inhibitor class. The company’s decision to discontinue the drug’s development program is based on an interim analysis of

Under the Prescription Drug User Fee Act (PDUFA), the FDA review of the resubmission for BiDil (a fixed combination of isosorbide dinitrate and hydralazine) is expected to be

The award, from the Department of Development Cooperation of the Netherlands Ministry of Foreign Affairs (DGIS), comes after the Dutch government concluded its presidency of the EU in

The randomized, controlled phase II study was designed to evaluate improved response when ProMune is added to standard chemotherapy compared to chemotherapy alone, in first-line treatment of advanced

The preliminary 48-week data is from Gilead’s Study 934, a phase III trial designed to compare a regimen of Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Sustiva (efavirenz)

A letter from Professor G. Duff, chairman of the Committee on Safety of Medicines, advised doctors and patients of the risk of incurring rare, but sometimes severe, liver